Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival

Transplantation

Volumn 94, Issue 2, 2012, Pages 145-151

  Numakura, Kazuyuki ^a   Satoh, Shigeru ^a   Tsuchiya, Norihiko ^a   Saito, Mitsuru ^a   Maita, Shinya ^a   Obara, Takashi ^a   Tsuruta, Hiroshi ^a   Inoue, Takamitsu ^a   Narita, Shintaro ^a   Horikawa, Yohei ^a   Kagaya, Hideaki ^b   Miura, Masatomo ^b   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AKITA UNIVERSITY   (Japan)

Author keywords

Allopurinol; Genetic polymorphism; Graft survival; Long term dialysis; Uric acid

Indexed keywords

ALLOPURINOL; DIPEPTIDYL CARBOXYPEPTIDASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE SYNTHASE; TACROLIMUS; URIC ACID;

ACE GENE; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; ENOS GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY TRANSPLANTATION; LONG TERM CARE; MALE; MTHFR GENE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

ADULT; AGED; ALLOPURINOL; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; HYPERURICEMIA; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; PARATHYROID HORMONE; PREVALENCE; TIME FACTORS; URIC ACID;

EID: 84864282528     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318254391b     Document Type: Article

References (49)

1. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000; 11: 974.
2. Perico N, Codreanu I, Caruso M, et al. Hyperuricemia in kidney transplantation. Contrib Nephrol 2005; 147: 124.
3. Armstrong KA, Johnson DW, Campbell SB, et al. Does uric acid have a pathogenetic role in graft dysfunction and hypertension in renal transplant recipients? Transplantation 2005; 80: 1565.
4. Haririan A, Nogueira JM, Zandi-Nejad K, et al. The independent association between serum uric acid graft outcomes after kidney transplantation. Transplantation 2010; 89: 573.
5. Gerhardt U, Grosse Huttmann M, Hohage H. Influence of hyperglycemia and hyperuricemia on long-term transplant survival in kidney transplant recipients. Clin Transplant 1999; 13: 375.
6. Lin HY, Rocher LL, McQuillan MA, et al. Cyclosporine-induced hyperuricemia and gout. N Engl J Med 1989; 321: 287.
7. Pascual M, Curtis J, Delmonico FL, et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003; 75: 1501.
8. Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67: 237.
9. Kato M, Hisatome I, Tomikura Y, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol 2005; 96: 1576.
10. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739.
11. Mazzali M, Kim YG, Suga S, et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001; 71: 900.
12. Abbott KC, Kimmel PL, Dharnidharka VD, et al. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation 2005; 80: 1383.
13. Hernandez-Molina G, Cachafeiro-Vilar A, Villa AR, et al. Gout in renal allograft recipients according to the pretransplant hyperuricemic status. Transplantation 2008; 86: 1543.
14. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384.
15. Manzia TM, De Liguori Carino N, Orlando G, et al. Use of mycophenolate mofetil in liver transplantation: a literature review. Transplant Proc 2005; 37: 2616.
16. Milijkovic Dj, Cvetkovic I, Stosic-Grujicic S, et al. Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts. Clin Exp Immunol 2003; 132: 239.
17. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80(2 suppl): S181.
18. Philip I, Plantefeve G, Vuillaumier-Barrot S, et al. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine. Circulation 1999; 99: 3096.
19. Weaver VM, Schwartz BS, Jaar BG, et al. Associations of uric acid with polymorphisms in the delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers. Environ Health Perspect 2005; 113: 1509.
20. Moriwaki Y, Yamamoto T, Tsutsumi Z, et al. Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol. Metabolism 2002; 51: 893.
21. Yamamoto T, Moriwaki Y, Takahashi S, et al. Effect of norepinephrine on the urinary excretion of purine bases and oxypurinol. Metabolism 2001; 50: 1230.
22. Li H, Ma Y, Fu Q, et al. Angiotensin-converting enzyme insertion/deletion (ACE I/D) and angiotensin II type 1 receptor (AT1R) gene polymorphism and its association with preeclampsia in Chinese women. Hypertens Pregnancy 2007; 26: 293.
23. Fodinger M, Wolfl G, Fischer G, et al. Effect of MTHFR 677C9T on plasma total homocysteine levels in renal graft recipients. Kidney Int 1999; 55: 1072.
24. Zuo M, Nishio H, Lee MJ, et al. The C677T mutation in the methylene tetrahydrofolate reductase gene increases serum uric acid in elderly men. J Hum Genet 2000; 45: 257.
25. Li S, Sanna S, Maschio A, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 2007; 31: e194.
26. Dehghan A, Kottgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008; 372: 1953.
27. Hamajima N, Okada R, Kawai S, et al. Significant association of serum uric acid levels with SLC2A9 rs11722228 among a Japanese population. Mol Genet Metab 2011; 103: 378.
28. Perez-Ruiz F, Gomez-Ullate P, Amenabar JJ, et al. Long-term efficacy of hyperuricaemia treatment in renal transplant patients. Nephrol Dial Transplant 2003; 18: 603.
29. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51.
30. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300: 924.
31. Assis SM, Monteiro JL, Seguro AC. L-Arginine and allopurinol protect against cyclosporine nephrotoxicity. Transplantation 1997; 63: 1070.
32. Barr WG. Uric acid. In Walker HK, Hall WD, Hurst JW, eds. Clinical Methods: The history, physical, and laboratory examinations. 3rd ed. Boston, MA: Butterworths; 1990: chap 165.
33. Akgul A, Bilgic A, Ibis A, et al. Is uric acid a predictive factor for graft dysfunction in renal transplant recipients? Transplant Proc 2007; 39: 1023.
34. Hakoda M. Epidemiology of hyperuricemia and gout in Japan. Nihon Rinsho 2008; 66: 647.
35. Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol 2005; 16: 1909.
36. Black DM, Greenspan SL, Ensrud KM, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 2003; 349: 1207.
37. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002; 13: 551.
38. Choi JY, YoonYJ,Choi HJ, et al. Dialysismodality-dependent changes in serum metabolites: accumulation of inosine and hypoxanthine in patients on haemodialysis. Nephrol Dial Transplant 2011; 26: 1304.
39. Schlesinger N. Dietary factors and hyperuricaemia. Curr Pharm Des 2005; 11: 4133.
40. Miller A, Adeli K. Dietary fructose and the metabolic syndrome. Curr Opin Gastroenterol 2008; 24: 204.
41. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010; 12: 223.
42. Neal DA, Tom BD, Gimson AE, et al. Hyperuricemia, gout, and renal function after liver transplantation. Transplantation 2001; 72: 1689.
43. Akalin E, Ganeshan SV, Winston J, et al. Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation 2008; 86: 652.
44. Haririan A, Metireddy M, Cangro C, et al. Association of serum acid with graft survival after kidney transplantation: a time-varying analysis. Am J Transplant 2011; 11: 1943.
45. Satoh S, Saito M, Inoue T, et al. CYP3A5*1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. Eur J Clin Pharmacol 2009; 65: 473.
46. Miura Y, Satoh S, Saito M, et al. Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year in living kidney transplant patients receiving tacrolimus. Transplantation 2011; 91: 78.
47. Numakura K, Satoh S, Tsuchiya N, et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantation 2005; 80: 1419.
48. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982.
49. Kagaya H, Miura M, Saito M, et al. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation. Basic Clin Pharmacol Toxicol 2010; 107: 631.